From the Q1 numbers:
"Our international medical cannabis sales during Q1 increased 11% to CAD5 million comprising 7% of our total consolidated net revenue."
From the article:
"The interruption, even if it ends up being very short, could be felt by the company after sales resume.
"The reason is patients who were using Aurora flower will now have to switch to another supplier in order to not interrupt treatment. A new prescription would be needed to go back to Aurora’s products after they become available, and doctors are normally hesitant to prescribe products that do not have a good track record of availability, according to medical and industry sources."
News 
Market Data 
Discover 
